ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
企業コードICCC
会社名ImmuCell Corp
上場日May 01, 1987
最高経営責任者「CEO」te Boekhorst (Olivier)
従業員数69
証券種類Ordinary Share
決算期末May 01
本社所在地56 Evergreen Drive
都市PORTLAND
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号04103
電話番号12078782770
ウェブサイトhttps://immucell.com/
企業コードICCC
上場日May 01, 1987
最高経営責任者「CEO」te Boekhorst (Olivier)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし